The fact that one person with the exon 21 mutation developed breast cancer and the other two with the exon 21 mutation are yet free from the disease suggest that the six common polymorphisms and the intron 7 variations are unlikely to predispose to or protect from the disease in exon 21 mutation carriers.
This mutation is yet to be identified.
No important, founder and frequent BRCA1 and BRCA2 mutation was yet reported in Australian studies [ 148].
Several VAPB mutations have been identified, but so far only a P56S mutation is yet known to co-segregate with disease [ 8, 9].
Although the molecular basis of the o7 mutation is yet unknown, it was shown that this mutation, in addition to repressing the lower molecular weight α-zeins, drastically affects the development of maize endosperm due to a reduction in starch content.
> -wrap-foot> In the field of molecular evolution, there are commonalities behind disease mutations which have been detected, but there are more complexities to disease mutations, which are yet to be discerned.
However, no such mutations are known yet for enzalutamide, and researchers are keen to understand whether they exist and, if so, to generate new drugs for prostate cancer that overcome them.
A number of disease-associated modifications involving the first 3 residues are known, including isomerisation, mutation, truncation and cyclisation, but are yet to be characterised in detail.
Next, mutation Cx32P87A is yet another cause of the CMTX disease; nonetheless it forms functional channels with properties that differ mildly from those of wild−type controls when expressed in pairs of Xenopus oocytes [23], [49].
However, the association between body size and CRC risk for MMR gene mutation carriers is yet to be established.
